On this page
ATAI Life Sciences N.V.
At 5% or more1
Filings2
Latest filing2025-10-20
ATAI Life Sciences N.V. has 2 Schedule 13D or 13G filings on record since 2025-08-18. 1 holder's latest filing reports 5% or more of ordinary shares, par value euro 0.10 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing identifies ATAI Life Sciences N.V. by CUSIP 45822R101 and gives its principal executive office as Wallstrasse 16, Berlin (SCHEDULE 13D/A, 2025-10-20).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Brenmiller Energy Ltd.
At 5% or more1
Filings7
Latest filing2025-10-21
Brenmiller Energy Ltd. has 7 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing identifies Brenmiller Energy Ltd. by CUSIP M2R43K404 and gives its principal executive office as 13 Amal St. 4th Floor, Park Afek, Rosh Haayin (SCHEDULE 13D/A, 2025-10-21).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Coca Cola Femsa Sab De Cv
At 5% or more1
Filings1
Latest filing2025-10-17
Coca Cola Femsa Sab De Cv has 1 Schedule 13D or 13G filing on record since 2025-10-17. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Coca Cola Femsa Sab De Cv, with its principal executive office as MARIO PANI #100, PISO 7, COL SANTA FE, CUAJIMALPA (SCHEDULE 13G/A, 2025-10-17).
Swipe the table sideways to see every column.
Cs Diagnostics Corp.
At 5% or more2
Filings2
Latest filing2025-10-07
Cs Diagnostics Corp. has 2 Schedule 13D or 13G filings on record since 2025-10-06. 2 holders' latest filing reports 5% or more of common stock (cusip 33852l202) and series b preferred stock (no cusip assigned). Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Cs Diagnostics Corp., with its principal executive office as STRESEMANNALLEE 4B, NEUSS (SCHEDULE 13G, 2025-10-07).
Swipe the table sideways to see every column.
Fitell Corporation
At 5% or more1
Filings1
Latest filing2025-10-02
Fitell Corporation has 1 Schedule 13D or 13G filing on record since 2025-10-02. 1 holder's latest filing reports 5% or more of class a ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Fitell Corporation, with its principal executive office as 23-25 Mangrove Lane, Taren Point NSW (SCHEDULE 13G, 2025-10-02).
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
Oatly Group AB
At 5% or more1
Filings2
Latest filing2025-10-17
Oatly Group AB has 2 Schedule 13D or 13G filings on record since 2025-09-02. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.00018 per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Oatly Group AB, with its principal executive office as Angfarjekajen 8, Malmo (SCHEDULE 13G/A, 2025-10-17).
The Reporting Persons beneficially own 10.3% of the outstanding Ordinary Shares based on (i) 606,215,240 Ordinary Shares outstanding as of June 30, 2025, as reported in the Company's Current Report on Form 6-K filed with the SEC on July 23, 2025 and (ii) the 8,148,385 Ordinary Shares represented by the Convertible Notes beneficially owned by the Reporting Persons.Platin S.a r.l., SCHEDULE 13G/A, 2025-10-17
Swipe the table sideways to see every column.
TurnOnGreen, Inc.
At 5% or more1
Filings3
Latest filing2025-10-30
TurnOnGreen, Inc. has 3 Schedule 13D or 13G filings on record since 2025-09-30. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing identifies TurnOnGreen, Inc. by CUSIP 45257M106 and gives its principal executive office as 1421 MCCARTHY BLVD., MILPITAS, CA 95035 (SCHEDULE 13D/A, 2025-10-30).
Item 3 is hereby amended and restated as follows: The aggregate purchase price of the 15,847,507 Shares beneficially owned by SJC were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases is $682,706, including brokerage commissions.Caspi Steven, SCHEDULE 13D/A, 2025-10-30
Swipe the table sideways to see every column.
Vast Renewables Ltd
At 5% or more3
Filings4
Latest filing2025-10-01
Vast Renewables Ltd has 4 Schedule 13D or 13G filings on record since 2025-07-01. 3 holders' latest filing reports 5% or more of ordinary shares, without par value. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names Vast Renewables Ltd, with its principal executive office as SUITE 7.02, 124 WALKER STREET, NORTH SYDNEY NSW (SCHEDULE 13G/A, 2025-10-01).
Swipe the table sideways to see every column.
XORTX Therapeutics Inc.
At 5% or more1
Filings1
Latest filing2025-10-27
XORTX Therapeutics Inc. has 1 Schedule 13D or 13G filing on record since 2025-10-27. 1 holder's latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Swipe the table sideways to see every column.
Swipe the table sideways to see every column.
The latest filing names XORTX Therapeutics Inc., with its principal executive office as 3710 - 33rd Street NW, Calgary (SCHEDULE 13G, 2025-10-27).
Swipe the table sideways to see every column.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
All 5%+ stakes
